Equities Analysts Issue Forecasts for Transcat, Inc.’s FY2025 Earnings (NASDAQ:TRNS)

Transcat, Inc. (NASDAQ:TRNS) – Research analysts at HC Wainwright decreased their FY2025 EPS estimates for shares of Transcat in a research report issued on Tuesday, April 16th. HC Wainwright analyst S. Buck now expects that the scientific and technical instruments company will post earnings per share of $2.31 for the year, down from their previous estimate of $2.41. HC Wainwright has a “Buy” rating and a $124.00 price target on the stock. The consensus estimate for Transcat’s current full-year earnings is $1.33 per share.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.03. Transcat had a net margin of 4.16% and a return on equity of 9.32%. The business had revenue of $65.17 million for the quarter, compared to analysts’ expectations of $63.36 million.

Other equities research analysts have also issued research reports about the stock. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price objective (up previously from $120.00) on shares of Transcat in a research note on Thursday. TheStreet upgraded shares of Transcat from a “c+” rating to a “b” rating in a research note on Wednesday, January 31st.

Transcat Price Performance

Shares of NASDAQ TRNS opened at $105.25 on Thursday. Transcat has a fifty-two week low of $74.89 and a fifty-two week high of $115.41. The stock has a market cap of $929.36 million, a price-to-earnings ratio of 80.96 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.81 and a current ratio of 3.37. The firm’s 50-day simple moving average is $108.59 and its 200 day simple moving average is $101.91.

Insider Transactions at Transcat

In other news, CEO Lee D. Rudow sold 5,000 shares of Transcat stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total transaction of $556,500.00. Following the completion of the sale, the chief executive officer now directly owns 108,478 shares of the company’s stock, valued at approximately $12,073,601.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Lee D. Rudow sold 5,000 shares of Transcat stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total value of $556,500.00. Following the transaction, the chief executive officer now owns 108,478 shares in the company, valued at approximately $12,073,601.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Lee D. Rudow sold 2,373 shares of Transcat stock in a transaction on Saturday, March 30th. The stock was sold at an average price of $111.43, for a total transaction of $264,423.39. Following the completion of the transaction, the chief executive officer now owns 103,688 shares in the company, valued at approximately $11,553,953.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,073 shares of company stock valued at $900,023. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Transcat

Large investors have recently added to or reduced their stakes in the business. Diversified Trust Co increased its position in shares of Transcat by 4.3% in the fourth quarter. Diversified Trust Co now owns 2,435 shares of the scientific and technical instruments company’s stock valued at $266,000 after acquiring an additional 100 shares during the period. White Pine Capital LLC increased its position in shares of Transcat by 1.5% in the third quarter. White Pine Capital LLC now owns 9,985 shares of the scientific and technical instruments company’s stock valued at $978,000 after acquiring an additional 144 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Transcat by 5.6% in the second quarter. The Manufacturers Life Insurance Company now owns 2,795 shares of the scientific and technical instruments company’s stock valued at $238,000 after acquiring an additional 148 shares during the period. FMR LLC increased its position in shares of Transcat by 3.8% in the first quarter. FMR LLC now owns 4,605 shares of the scientific and technical instruments company’s stock valued at $412,000 after acquiring an additional 167 shares during the period. Finally, Commonwealth Equity Services LLC increased its position in shares of Transcat by 4.2% in the third quarter. Commonwealth Equity Services LLC now owns 4,377 shares of the scientific and technical instruments company’s stock valued at $429,000 after acquiring an additional 175 shares during the period. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Transcat

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.